This HTML5 document contains 125 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n11http://dx.doi.org/10.1007/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
n7https://scigraph.springernature.com/pub.10.1007/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q33374707
rdf:type
wikibase:Item
schema:description
2007年論文 tudományos cikk სამეცნიერო სტატია 2007년 논문 scienca artikolo מאמר מדעי articol științific vedecký článok mokslinis straipsnis article scientifique (publié 2007) мақолаи илмӣ επιστημονικό άρθρο teaduslik artikkel научная статья 2007年論文 vědecký článek 2007年论文 artículu científicu espublizáu en 2007 artículo científico publicado en 2007 videnskabelig artikel (udgivet 2007) 2007 nî lūn-bûn artikull shkencor مقالة علمية 2007年论文 artykuł naukowy artigo científico (publicado na 2007) artigo científico 2007年論文 سائنسی مضمون 2007年论文 مقالهٔ علمی vitenskapelig artikkel наукова стаття, опублікована в березні 2007 article scientific научни чланак научни чланак научна статия article científic 2007年の論文 2007年论文 ২০০৭-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ articolo scientifico wissenschaftlicher Artikel 2007年論文 artigo científico (publicado na 2007) vitskapeleg artikkel บทความทางวิทยาศาสตร์ 2007年論文 2007年论文 мақолаи илмӣ 2007 թուականի Մարտին հրատարակուած գիտական յօդուած bilimsel makale naučni članak vetenskaplig artikel wetenschappelijk artikel 2007 թվականի մարտին հրատարակված գիտական հոդված artikulong pang-agham 2007年论文 scientific article tieteellinen artikkeli bài báo khoa học
p:P577
wds:Q33374707-90FECF45-8021-4C0A-B967-F000092A1F3F
wdt:P577
2007-03-29T00:00:00Z
p:P2888
wds:Q33374707-FE450672-03E3-4D2F-8B9D-D0CB0ADEABEF
wdt:P2888
n7:s00280-006-0336-0
p:P2093
wds:Q33374707-1C725D23-1696-45DD-B0BC-73B1838A2989
wdt:P2093
Masahiro Tabata
rdfs:label
A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer
skos:prefLabel
A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer
schema:name
A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer
p:P50
wds:Q33374707-A0FA1996-EECD-4A6D-9738-BE5B0DC9993B wds:Q33374707-D0FB516C-E285-4C20-BADA-9D505190E26D wds:Q33374707-6585C82B-88D3-4527-8AEB-BAED98667CB7 wds:Q33374707-68A975D7-8F40-4225-9F64-0881088CB733 wds:Q33374707-7D0746C5-02DB-4DB3-B0DE-29552C9161EA wds:Q33374707-89384FCF-8F39-4B65-932D-385562C49F74 wds:Q33374707-E59E661B-976E-4D53-955D-9D4BF75CA0CC wds:Q33374707-1B683B13-D7D4-4EEF-8D3E-03B69E8F4846 wds:Q33374707-4BA7324A-EF90-441C-A7E7-D28903F2623E wds:Q33374707-589B3EF7-27A0-4374-A378-2AEFF5F3CE37
wdt:P50
wd:Q114418761 wd:Q114418737 wd:Q71779893 wd:Q71792097 wd:Q91655587 wd:Q114418735 wd:Q114418730 wd:Q114418774 wd:Q114418760 wd:Q114418746
p:P1476
wds:Q33374707-DF4D3435-DDAD-412E-9E2A-C409C9A66AD4
wdt:P1476
A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer
p:P304
wds:Q33374707-9931F45F-5607-44D4-9678-DED4635F5B5A
wdt:P304
1-6
p:P31
wds:Q33374707-DAC36D8B-6A95-44AB-B77E-7EC1C501D0BC
wdt:P31
wd:Q13442814
p:P921
wds:Q33374707-D0288CCD-74FF-43AA-A078-872DBB08B770 wds:Q33374707-62D2B592-5F42-40CE-91AD-930E9A9162CF wds:Q33374707-800B110C-AB42-4B6C-861B-AA2F0F9A3F86 wds:Q33374707-81D46F41-BC92-49FD-B20C-8D3B9E98DC75
wdt:P921
wd:Q418817 wd:Q18936 wd:Q42824440 wd:Q412197
p:P698
wds:Q33374707-9246959B-FB71-45EE-B969-385CACD35C02
wdtn:P698
n13:17393168
wdt:P698
17393168
p:P1433
wds:Q33374707-6B58915A-34D2-4C30-A37C-A08A82398D98
wdt:P1433
wd:Q326137
p:P433
wds:Q33374707-9C566FA1-E584-4AF3-B6A3-7481716473C6
p:P478
wds:Q33374707-53EB62E7-C4A5-4CA3-8999-3F86F02A722D
wdt:P433
1
wdt:P478
60
p:P356
wds:Q33374707-4BD69027-33A8-48DD-A040-A4D4850A746B
wdtn:P356
n11:S00280-006-0336-0
wdt:P356
10.1007/S00280-006-0336-0
p:P6179
wds:Q33374707-3347AE61-696C-4E55-A458-38A80450C9C4
wdt:P6179
1021474543